Jaguar Animal Health Inc
$ 2.31
-6.48%
16 Jun - close price
- Market Cap 1,740,100 USD
- Current Price $ 2.31
- High / Low $ 2.56 / 2.29
- Stock P/E N/A
- Book Value -38.12
- EPS -695.50
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.36 %
- ROE -4.12 %
- 52 Week High 115.50
- 52 Week Low 2.29
About
Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.
Analyst Target Price
$262.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-05-14 | 2024-01-31 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-27 |
| Reported EPS | -6.28 | -10.26 | -18.7722 | -125.8 | -1.05 | -4.04 | -0.07 | -33 | -0.55 | -0.69 | -2.3881 | -3.4297 |
| Estimated EPS | -0.22 | -0.28 | -10.82 | -18.5 | -2.37 | -1.2 | -0.03 | -73.8 | -1.23 | -1.53 | -0.04 | -9.75 |
| Surprise | -6.06 | -9.98 | -7.9522 | -107.3 | 1.32 | -2.84 | -0.04 | 40.8 | 0.68 | 0.84 | -2.3481 | 6.3203 |
| Surprise Percentage | -2754.5455% | -3564.2857% | -73.4954% | -580% | 55.6962% | -236.6667% | -133.3333% | 55.2846% | 55.2846% | 54.902% | -5870.25% | 64.8236% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: JAGX
2026-06-12 09:00:00
Jaguar Health, Inc. announced that its CEO, Lisa Conte, will present virtually on June 24, 2026, at the Life Sciences Virtual Investor Forum, providing updates on the company's crofelemer development program for rare intestinal failure diseases. The company also highlighted two upcoming crofelemer presentations focusing on pediatric intestinal failure patients with microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) at the 2026 ESPGHAN Annual Meeting. Jaguar Health specializes in developing plant-derived prescription drugs for complicated gastrointestinal conditions.
2026-06-11 12:39:13
Jaguar Health has announced two financial transactions to bolster its liquidity. The company secured an equity line of credit of up to $40 million with an institutional investor and simultaneously closed a $2 million private placement of Series P Non-Convertible Preferred Stock. These funds are intended for general corporate purposes and will involve the filing of related resale registration statements on Form S-1.
2026-06-11 12:39:13
Jaguar Health (NASDAQ: JAGX) has secured two new financing deals: a $40 million equity line of credit (ELOC) with an institutional investor and a $2 million private placement of Series P preferred stock. The ELOC allows for purchases of common stock up to $40 million, subject to volume and ownership limits, while the preferred shares carry an 8% annual dividend and complex redemption mechanics. These agreements aim to bolster capital access and liquidity, although they introduce potential dilution and structural complexity to the capital base.
2026-06-10 14:10:08
Jaguar Health shareholders have approved new financing and governance proposals, including a potential equity line of credit, to address the biotech company's funding needs. This move aims to provide more predictable access to capital while acknowledging the risk of dilution for existing investors. The company focuses on developing and commercializing prescription medicines for gastrointestinal conditions, and its stock has experienced significant volatility.
2026-06-09 06:09:22
Jaguar Health, Inc. announced that all five proposals presented at its reconvened Annual Meeting of Stockholders on June 8, 2026, were approved. Details of these proposals are available in the company's proxy statement filed with the SEC. Additionally, Lisa Conte, Jaguar's CEO, will present virtually at the Emerging Growth Conference on June 10, 2026.
2026-06-09 04:40:38
Jaguar Health Inc. (NASDAQ:JAGX) stockholders approved five proposals at their annual meeting. The company also announced that CEO Lisa Conte will present at the Emerging Growth Conference. Despite a 98% stock decline over the past year, Jaguar Health recently reported an 816% revenue surge for Q1 2026 and regained Nasdaq compliance.
